This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Health Policy  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

The Australian Pharmaceutical Benefits Scheme

David A. Henry, MB, FRCP; Suzanne R. Hill, MBBS, PhD, FAFPHM; Anthony Harris, MA, MSc

JAMA. 2005;294:2630-2632.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of JAMA, Pearson and Rawlins¹ describe the work of the National Institute for Health and Clinical Excellence (NICE), the main health technology assessment agency in the United Kingdom. NICE provides comprehensive advice, including assessment of efficacy and comparative cost-effectiveness of medical interventions and publishes clinical guidelines.² This ambitious project is the most prominent and far reaching of a number of international initiatives, including health technology assessment programs in Canada and Spain^3-4 and pharmaceutical cost-effectiveness evaluations linked to reimbursement decisions in Australia, the Netherlands, and Canada.^5-7 The relevance to the United States has increased with the Medicare Prescription Drug Improvement and Modernization Act of 2003.⁸ This act introduces a voluntary program of prescription drug coverage but the US government will not get directly involved in price negotiation, leaving implementation of the drug . . . [Full Text of this Article]

Australian Pharmaceutical Benefits Scheme

Independence From Government

Relationship With the Pharmaceutical Industry

Transparency

Methodology

Cost-effectiveness Ratios and Budgets

Criticisms

Author Affiliations: School of Medicine and Public Health, University of Newcastle, New South Wales (Drs Henry and Hill) and Centre for Health Economics, Monash University, Victoria (Dr Harris), Australia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions: A Comparison of Britain, Australia, and Canada
Clement et al.
JAMA 2009;302:1437-1443.
ABSTRACT | FULL TEXT  

Left ventricular assist device as destination therapy: application of the payment-by-results approach for the device reimbursement.
Messori et al.
J. Thorac. Cardiovasc. Surg. 2009;138:480-485.
ABSTRACT | FULL TEXT  

Controversies in Using Lapatinib at Reduced Dosage With Food
Trippoli
JCO 2007;25:5333-5333.
FULL TEXT  

The Value Meal: Effect of Food on Lapatinib Bioavailability
Rahman et al.
JCO 2007;25:5333-5334.
FULL TEXT  

Simplified Pharmacoeconomics of Critical Care and Severe Sepsis
Ernst et al.
J Intensive Care Med 2007;22:283-293.
ABSTRACT  

Medicare And Cost-Effectiveness Analysis: Time To Ask The Taxpayers
Gold et al.
Health Aff (Millwood) 2007;26:1399-1406.
ABSTRACT | FULL TEXT  

Linking Cost Sharing to Value: An Unrivaled Yet Unrealized Public Health Opportunity
Braithwaite and Rosen
ANN INTERN MED 2007;146:602-605.
ABSTRACT | FULL TEXT  

Cost-effectiveness and Resource Allocation
Cohen
JAMA 2006;295:2723-2723.
FULL TEXT